Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.pfizer.com › news › press-releasePfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection...

   www.pfizer.com › news › press-release

   • Zapisane w pamięci cache

   15 lut 2022 · Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to ...

   • Pfizer and OPKO’s Once-Weekly NGENLATM

     NEW YORK & MIAMI--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE)...

   • FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for ...

     New, longer-acting treatment offers option to reduce the...

   • OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting ...

     OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE)...

2. www.pfizer.com › news › press-releaseFDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly...

   www.pfizer.com › news › press-release

   • Zapisane w pamięci cache

   28 cze 2023 · New, longer-acting treatment offers option to reduce the frequency of injections for children with growth hormone deficiency from daily to once-weekly. NEW YORK & MIAMI-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA ...

3. www.pfizer.com › news › press-releaseOPKO and Pfizer Enter into Global Agreement for OPKO’s...

   www.pfizer.com › news › press-release

   • Zapisane w pamięci cache

   15 gru 2014 · OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for ...

4. insights.pfizer.com › pfizer-and-opkos-once-weekly-ngenlasomatrogon-injectionPfizer and OPKO’s Once-Weekly NGENLA™(somatrogon) Injection...

   insights.pfizer.com › pfizer-and-opkos-once-weekly-ngenlasomatrogon-injection

   15 lut 2022 · Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency. February 15, 2022. Share.

5. www.nasdaq.com › press-release › pfizer-and-opkos-once-weekly-ngenlatm-somatrogonPfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon ... - Nasdaq

   www.nasdaq.com › press-release › pfizer-and-opkos-once-weekly-ngenlatm-somatrogon

   • Zapisane w pamięci cache

   15 lut 2022 · NEW YORK & MIAMI -- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the...

6. pubmed.ncbi.nlm.nih.gov › 35041176Somatrogon: First Approval - PubMed

   pubmed.ncbi.nlm.nih.gov › 35041176

   Somatrogon (NGENLA ®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients.

7. link.springer.com › article › 10Somatrogon: First Approval | Drugs - Springer

   link.springer.com › article › 10

   • Zapisane w pamięci cache

   18 sty 2022 · Somatrogon (NGENLA®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients.